Literature DB >> 10713647

Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus.

A Spadaro1, V Riccieri, S Terracina, T Rinaldi, E Taccari, A Zoppini.   

Abstract

The relationship of rheumatoid factors (RF) with antiphospholipid syndrome (aPLS) and anticardiolipin antibodies (aCL) has rarely been investigated in systemic lupus erythematosus (SLE). We found IgM-RF, IgG-RF, IgA-RF, IgM-aCL, IgG-aCL, IgA-aCL, respectively, in 35.4%, 35.4%, 33.8%, 23.1%, 23.1%, 20.0% of 65 SLE patients. Class specific RFs were negatively associated (P<0.05) with IgG-aCL. The frequency of definite or probable aPLS according to Alarcon-Segovia classification criteria was significantly (P<0.05) different (8.7% vs 30.9%) in patients with or without IgG-RF. Among the other clinical features of SLE, we found that patients with IgG-RF, compared to patients lacking this autoantibody, showed a lower frequency (P<0.05) of serositis (21.7% vs 52.4%) and hematologic (52. 2% vs 80.9%) disorders. The levels of IgG-RF and IgM-RF negatively correlated with the number of ARA criteria (P<0.05) but not with the indices of diseases activity or damage. Our study shows that in SLE the presence of RFs are not markers of severity of the disease, but the negative association between IgG-RF and IgG-aCL suggests a distinct role of these autoantibodies in the pathology of SLE, whereas the presence of IgG isotype may identify a subset of SLE patients having a lower risk to develop some clinical manifestations such as aPLS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713647     DOI: 10.1177/096120330000900110

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

Review 1.  Antiphospholipid antibodies in rheumatoid arthritis: identifying the dominoes.

Authors:  Debbie A Gladd; Ewa Olech
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

2.  Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  M Samarkos; K A Davies; C Gordon; S Loizou
Journal:  Clin Rheumatol       Date:  2005-08-10       Impact factor: 2.980

Review 3.  Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies.

Authors:  Laura Andreoli; Micaela Fredi; Cecilia Nalli; Silvia Piantoni; Rossella Reggia; Francesca Dall'Ara; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

4.  The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians.

Authors:  Juan-Sebastian Franco; Nicolás Molano-González; Monica Rodríguez-Jiménez; Yeny Acosta-Ampudia; Rubén D Mantilla; Jenny Amaya-Amaya; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.